The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Hydroxychloroquine probably provides no post-exposure benefit when taken within 4 days of COVID exposure.
pearl -
Randomized Controlled Trial Multicenter Study Comparative Study
Subcutaneous or Transvenous Defibrillator Therapy.
The subcutaneous implantable cardioverter-defibrillator (ICD) was designed to avoid complications related to the transvenous ICD lead by using an entirely extrathoracic placement. Evidence comparing these systems has been based primarily on observational studies. ⋯ In patients with an indication for an ICD but no indication for pacing, the subcutaneous ICD was noninferior to the transvenous ICD with respect to device-related complications and inappropriate shocks. (Funded by Boston Scientific; PRAETORIAN ClinicalTrials.gov number, NCT01296022.).